Yes, the company totally blew the PR. But I disagree re AF he was mentioning slamming CUR for months on Twitter feed. He mentioned he was waiting to put together a hit piece, and made disparaging remarks re the co and the science. The ill timed, poorly written article gave him the fuel.
BTW, Dr Feldman has a new article on JAMA set for release. Online only for now , 1st page free. Probably out in next issue. Even on the 1st page it addresses that there were varied patients in trials. Meaning, purposely not patients that fit into criteria. They were testing the waters to hone specificity. So, non-responders.